This press release and the webcast contain or may contain forward-looking information about, among other topics, Pfizer’s and Seagen’s anticipated operating and financial performance and expectations for Pfizer’s and Seagen’s product pipeline, in-line products and product candidates (including reve...
Pfizer Press release Research and Pipeline Research Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024 Wednesday, September 11, 2024 - 06:45am More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational ...
This press release and the webcast contain or may contain forward-looking information about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; reorganizations; business plans, strategy, goals and prospects; expectations for ...
I'm also proud of our strong year of pipeline progress in 2024, including more than a dozen approvals, seven pivotal study starts and eight key Phase 3 readouts. I'm very excited with the changes in our R&D engine under its new leaders. Chris Boshoff moved fast to create four end-to...
I'm also proud of our strong year of pipeline progress in 2024, including more than a dozen approvals, seven pivotal study starts and eight key Phase 3 readouts. I am very excited with the changes in our R&D engine under its new leadership. Chris Boshoff moved fast to create four end...
"While we see several assets in Pfizer's pipeline (particularly in oncology) that could make the story more interesting, we believe that further advancement ... will be necessary to change the current narrative on shares which would primarily occur 2026+," JP Morgan analyst Chris Schott wrote ...
pipeline in 2024 with phase 3 studies for sigvotatug vedotin, our integrin beta-6 directed ADC; atirmociclib, our selective CDK4 inhibitor; Elrexfio in the second-line setting in relapsed refractory multiple myeloma; and mevrometostat, our EZH2 inhibitor, which we are now moving to phase ...
Citi analyst Andrew Baum said that Pfizer's management is acting with increasing urgency to address its weak stock performance. However, the absence of promising high-potential pipeline assets makes it difficult for the company as several Pfizer products are expected to go off patent in the next ...
Research and Pipeline Social Responsibility Vaccines October 2024 10.22.2024 Corporate Partnerships Pfizer Supplies One Billionth Pneumococcal Conjugated Vaccine Dose for Vaccination of Children in Lower- Income Countries Through Gavi, the Vaccine Alliance ...
Sumitomo Pharma is a biopharmaceutical company focused on developing therapeutic and scientific breakthroughs. The company's main offerings include the development of novel cancer therapeutics and a robust pipeline of treatments aimed at addressing unmet clinical needs in oncology. Sumitomo Pharma was former...